LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Open

SectorHealthcare

223.58 -1.92

Buy Sell

Overview

Share price change

24h

Current

Min

222.2

Max

232

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+28.94% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.2B 15B
Previous open	225.5
Previous close	223.58

News Sentiment

By Acuity

54%

46%

281 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 mar 2026, 23:12 UTC

Hot Stocks

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12 mar 2026, 22:15 UTC

Earnings

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12 mar 2026, 21:42 UTC

Major News Events

Stryker Says Cyberattack Disruption Is Continuing

12 mar 2026, 21:29 UTC

Major News Events

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12 mar 2026, 21:27 UTC

Earnings

Adobe CEO to Depart as AI Boosts Sales -- Update

12 mar 2026, 20:46 UTC

Earnings

Adobe Posts Higher Sales With CEO Set to Depart

12 mar 2026, 20:21 UTC

Major News Events

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12 mar 2026, 23:57 UTC

Market Talk

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12 mar 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 mar 2026, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12 mar 2026, 22:13 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

12 mar 2026, 22:13 UTC

Market Talk

Earnings

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12 mar 2026, 21:16 UTC

Acquisitions, Mergers, Takeovers

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12 mar 2026, 21:04 UTC

Earnings

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12 mar 2026, 21:02 UTC

Earnings

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12 mar 2026, 21:02 UTC

Earnings

Wheaton Precious Metals 4Q Sales $865M >WPM

12 mar 2026, 21:02 UTC

Earnings

Wheaton Precious Metals 4Q Net $558.3M >WPM

12 mar 2026, 21:02 UTC

Earnings

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12 mar 2026, 20:57 UTC

Market Talk

Major News Events

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12 mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 mar 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12 mar 2026, 20:10 UTC

Earnings

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12 mar 2026, 20:05 UTC

Earnings

Adobe 1Q Rev $6.4B >ADBE

12 mar 2026, 20:05 UTC

Earnings

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

28.94% upside

12 Months Forecast

Average 293.33 USD 28.94%

High 342 USD

Low 255 USD

Based on 12 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

281 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.